Gyre Therapeutics (GYRE) Gains from Investment Securities (2010 - 2026)
Gyre Therapeutics (GYRE) reported Gains from Investment Securities of -$89000.0 for Q1 2026, down 100.5% year-over-year from $17.8 million in Q1 2025, and up 96.71% quarter-over-quarter from -$2.7 million in Q4 2025.
Gyre Therapeutics (GYRE) Gains from Investment Securities (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 17 years of Gains from Investment Securities data on file, last reported at -$89000.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at -$89000.0, down 100.5% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.0 million (down 116.8% YoY), and the FY2025 annual result was $19.5 million, up 7.77% from the prior year.
- Gains from Investment Securities grew to -$89000.0 in Q1 2026 per GYRE's latest filing, from -$2.7 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $18.5 million in Q3 2024 and troughed at -$5.3 million in Q4 2023.
- A 5-year average of $5.2 million and a median of $340973.5 in 2022 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2022 and 2025: Gains from Investment Securities soared 1309.68% in 2022, then sank 135350.0% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $17.0 million in 2022, then plunged by 131.02% to -$5.3 million in 2023, then soared by 100.04% to $2000.0 in 2024, then slumped by 135350.0% to -$2.7 million in 2025, then soared by 96.71% to -$89000.0 in 2026.
- Business Quant data shows GYRE's Gains from Investment Securities at -$89000.0 in Q1 2026, -$2.7 million in Q4 2025, and $23000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -89,000.00 |
| Mar 31, 2026 | -89,000.00 |
| Dec 31, 2025 | -2.71 Mn |
| Dec 31, 2025 | -2.71 Mn |
| Sep 30, 2025 | 23,000.00 |
| Sep 30, 2025 | 23,000.00 |
| Jun 30, 2025 | -212,000.00 |
| Jun 30, 2025 | -212,000.00 |
| Mar 31, 2025 | 17.76 Mn |
| Mar 31, 2025 | 17.76 Mn |
| Dec 31, 2024 | 2,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Sep 30, 2024 | 18.55 Mn |
| Sep 30, 2024 | 18.55 Mn |
| Jun 30, 2024 | -2.91 Mn |
| Jun 30, 2024 | -2.91 Mn |
| Mar 31, 2024 | 18.22 Mn |
| Mar 31, 2024 | 18.22 Mn |
| Dec 31, 2023 | -5.29 Mn |
| Dec 31, 2023 | -5.29 Mn |